U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO	Complete if Known		
INFORMATION DISCLOSURE	Application Number	10/748,124	
TO THE EMENT BY APPLICANT	Filing Date	12/31/2003	
Date Submitted: July 30, 2004	First Named Inventor	Scott UMLAUF	
b .7	Group Art Unit	Unassigned_ \{\}	
(use as many sheets as necessary)	Examiner Name	Unassigned RIWH+ CAL	
Sheetypared 1 of 3	Attorney Docket Number	036481-0146	

Examiner Initials*		U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant	
	Cite No. <sup>1</sup>	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
2	A1	US 4,945,050		SANFORD et al.	107-31-1990	<b>^</b>	
	A2	US 5,100,792	Α	SANFORD et al.	03 31-1992		
	A3	US 5,120,657	Α	McCABE et al.	06-09-1992		
	A4	US 5,149,655	Α	McCABE et al.	09-22-1992		
	A5	US 5,187,077	Α	GEARING et al.	02-16-1993		
	A6	US 5,204,253	Α	SANFORD et al.	04-20-1093		
	A7	US 5,584,807	Α	McCABE	12-17-1908		
1	A8	US 5,589,466	Α	FELGNER et al.	12-31-1926		
	A9	US 5,630,796	Α	BELLHOUSE et al.	05-20-1,697		
	A10	US 5,738,852	Α	ROBINSON et al.	04-14-1998		
	A11	US 5,865,796	Α	McCABE	02-02-1999		
	A12	US 6,168,587	B1	BELLHOUSE et al.	01-\$62-2001		
Ð	A13	US 6,194,389	B1	JOHNSTON et al.	02/27-2001		
P	A14	US 6,339,068	B1	KREIG et al.	01-15-2002	\	

				FC	DREIGN PATENT DOCUMEN	TS		
Examin er Initials*	Cite No.1	Fo Office <sup>3</sup>	oreign Patent D Number <sup>4</sup>	ocument Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figwes Appear	₹6
Br.	A15	wo	94/24263	A1	OXFORD BIOSCIENCES LIMITED	0-27-94		
	A16	wo	96/04947	A1	OXFORD BIOSCIENCES LIMITED	02\22-1996		
	A17	wo	96/12513	A1	OXFORD BIOSCIENCES LIMITED	05-03-1996		
	A18	wo	96/14855	A1	AGRACETUS, INC.	05-23-1996		
	A19	wo	96/20022	A1	OXFORD BIOSCIENCES LIMITED	07-04-1996		
	A20	wo	97/32987	A1	UNIVERSITY OF TORONTO	09-12-1997		
	A21	wo	97/48485	A1	POWDERJECT RESEARCH LIMITED	12-24-1997		
	A22	wo	98/10750	A2	POWDERJECT RESEARCH LIMITED	03-19-1998		
8	A23	wo	98/28332	A2	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM	07-02-1998		
								<u> </u>

Examiner Signature	Pri 1 sto		Date Considered	VIUN
		المستناف التناف المستناف		<u> </u>

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO	Complete if Known		
INFORMATION DISCLOSURE	Application Number	10/748,124	
STATEMENT BY APPLICANT	Filing Date	12/31/2003	
JUL 3 0 200 Bate Submitted: July 30, 2004	First Named Inventor	Scott UMLAUF	
III 3 0 20 Date Submitted: July 30, 2004	Group Art Unit	Unassigned 1/1	
(use as many sheets as necessary)	Examiner Name	Unassigned	
(use ds many sheets as necessary)  Sheet of 3	Attorney Docket Number	036481-0146	

		NON PATENT LITERATURE DOCUMENTS	_	
Examiner nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
K-	A24	ARMITAGE et al., Nature (1992), 357:80-82.		
	A25	BRANKENHOFF et al., Immunol. (1987), 139:4116-4121.		
1	A26	CHEN et al., Journal of the American Society of Hematology (1995), 86(10):Abstract No. 963.		
	A27	ELLIS et al., J. Immunol. (1996), 56:2700-2709.		
<b>-</b>	A28	FONG et al., J. Immunol. (1996), 157:4442-4450.	T	
1	A29	FREEMAN et al., <i>Immunology</i> , 2 <sup>no</sup> Ed. (1994), pp. 19-20, 89-90, 103-106 and 297-298.		
+	A30	FREEMAN et al., Science (1993), 262:909-911.		
	A31	GURUNATHAN et al., J. Immunol. (1998), 161:4563-4571.		
$\neg \vdash$	A32	JENKINS, M.K., <i>Immunol. Today</i> (1992), 13:69-73.	T	
	A33	JOSIEN et al., J. Immun. (1999), 162:2562-2568.	T	
_	A34	LAI et al., DNA and Cell Biol. (1995), 14:643-641.	T	
	A35	LI et al., "Cloning and Functional Characterization of the 5'-Regulatory Region of the Human CD86 Gene," Human Immunology (2000), 61:486-498.		
	A36	LIU, Y. et al., J. Exp. Med. (1992), 175:437-445.		
	A37	LYMAN, et al., Oncogene (1995), 11(6):1165-72.		
	A38	MACKEY et al., J. Immunology (1998), 161:2094-2098.		
	A39	MANIATIS, et al., Molecular Clonging: Laboratory Manual, Cold Spring Harbor: 406-407.		
	A40	MENDOZA et al., J. Immunology (1997), 159:5777-5781.	T	
	A41	MORGAN et al., Science (1976), 193:1007-1008.	1	
	A42	NABAVI et al., Nature (1992), 360:266-268.	T	
1	A43	NAUJOKAS, M.F., et al., Cell (1993), 74:257-268.		
	A44	NGO et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," In: The Protein Folding Problem and Tertiary Structure Prediction. (1994), Ch. 14: 491-494.		
4	A45	PULENDRAN et al., J. Exp. Med., 188:2075-2082, 1998	1	
1/2	A46	ROMANI et al., J. Invest. Dermatol. (1989), 93:600-609.	T	

Examiner Signature	Date Consider	red 7 13/01

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 
<sup>5</sup>Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute	for form 1449B/PTO		Complete if Known		
O I P ENFORMA	TION DISCLOSURE	Application Number	10/748,124		
STATEME	NT BY APPLICANT	Filing Date	12/31/2003		
/ Coto Gubi	mittad: July 30, 2004	First Named Inventor	Scott UMLAUF		
B JUL 3 0 2004 U.	ilited. July 30, 2004	Group Art Unit	Unassigned \ ()		
(use as man	y sheets as necessa	y) Examiner Name	Unassigned		
Sheet 3	of 3	Attorney Docket Numbe	r 036481-0146		

		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	1
Examiner Cite Initials* No.		item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T⁰
Pt	A47	SCHULER et al., J. Exp. Med. (1985), 161:526-546.	
	A48	SCHWARTZ, R.H., Cell (1992), 71:1065-1068.	T
	A49	SCHWARTZ, R.H., Science (1990), 248:1349-1356.	T
	A50	SELVAKUMAR et al., Immunogenetics (1993), 38:292-295.	
_	A51	SPRIGGS et al., J. Exp. Med. (1992), 176:1543-1550.	T
	A52	SPRIGGS, Immunol Ser. (1992), 56:3-34.	
A53		TACKET et al., "Phase 1 Safety and Immune Response Studies of a DNA Vaccine Encoding Hepatitis B Surface Antigen Delivered by a Gene Delivery Device," Vaccine (1999), 17:2826-2829.	
	A54	VAN SEVENTER, G.A., J. Immunol. (1990), 144:4579-4586.,	
	A55	WONG et al., J. Biol Chem (1997), 272(40):25190-4.	
	A56	WONG et al., J. Exp. Med. (1997), 186:2075-2080.	+
$\top$	A57	WONG et al., J. Immunol. (1999), 162:2251-2258.	
R	A58	ZHANG et al., Gene (1996), 183:1-6.	T

Examiner Signature	P~ 1/1	Date Considered	ZIVA

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English tanguage Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.